New top 10 global entry by merger

0

The final agreement for the acquisition of Allergan by Actavis has been signed; the transaction is valued $66 billion. The new company will be positioned among the top ten global pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015. As Actavis anticipated, the expected permanent financing structure, consisting of a combination of new equity and debt, will support an investment grade rating and provide long-term financing flexibility.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here